Delivery Order SPE2DB22D9239-SPE2DB26FDD78

The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $22,020.61 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cerdelga 84 mg capsules (14-count units). The delivery order, issued on October 27, 2025, with completion targeted for November 18, 2025, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for the Department of Defense. This underlying contract, valued at up to $499,999,999 with a performance period extending through December 31, 2036, authorizes the issuance of delivery orders for branded and generic prescription medications, over-the-counter drugs, biologics, and medical consumables to support military healthcare facilities worldwide.

As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated substantial contracting activity with the Defense Logistics Agency's Medical Supply Chain division, fulfilling diverse and specialized pharmaceutical requirements across multiple therapeutic categories including oncology treatments, immunosuppressants, vaccines, and emergency medications. The company's established performance record on numerous delivery orders issued between October 2 and October 15, 2025—ranging from minimal purchases to awards exceeding $115,000—reflects its competitive capability and operational readiness to support Department of Defense healthcare operations globally under the PPV-G GEN V program structure.